Archived Monthly Oncology Tumor Boards: Treatment of Patients with Bladder and Upper Tract Urothelial Cancer
Education on the appropriate use of newly approved therapies and considerations for treatment planning and side effect management can benefit clinicians interested in incorporating these therapies into their clinical practice.
Category
- Bladder Cancer
- Genitourinary Cancers
Format
- Recorded Webcast
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- CCM clock hours
- Participation
NCCN Guidelines® Insights - Survivorship, Version 1.2022
This article summarizes updates to the NCCN Guidelines pertaining to preventive health for cancer survivors, including recommendations about alcohol consumption and vaccinations.
Category
- Survivorship
Format
- Monograph/Journal Supplement
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- ASWB continuing education credit
- Participation
Recorded Presentation from the NCCN Pharmacy Updates: Updates in the Management of Indolent Non-Hodgkin Lymphomas
Pharmacists play a critical role in patient education, monitoring, and management of treatment-related toxicities and would benefit from a comprehensive review of the novel treatments for indolent non-Hodgkin lymphomas.
Category
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- Participation
Archived Monthly Oncology Tumor Boards: Treatment of Patients with Kidney Cancer
Adjuvant treatment options for patients with advanced renal cell carcinoma (RCC) following surgery are continually evolving, and new treatment options for different stages of RCC are being approved. It can be challenging for clinicians to remain up-to-date on these updates.
Category
- Kidney Cancer
Format
- Live Webinar
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- CCM clock hours
- Participation
Recorded Presentation from the NCCN Pharmacy Updates: Novel Therapies for the Treatment of Metastatic Breast Cancer
Pharmacists should be aware of the new data and recommendations surrounding novel agents and how they relate to improvements in patient survival and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies.
Category
- Breast Cancer
Format
- Recorded Webcast
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- Participation
NCCN Guidelines® Insights - Gastrointestinal Stromal Tumors, Version 2.2022
Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes.
Category
- Soft Tissue Sarcomas
Format
- Monograph/Journal Supplement
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- Participation
Archived Monthly Oncology Tumor Boards: Esophageal and Esophagogastric Junction Cancers: Postoperative Therapy in Patients with Residual Disease
Clinicians should regularly evaluate recent clinical trial data to make informed decisions on the most appropriate treatment plan, particularly as new targeted therapies, as well as new indications for existing targeted therapies, become FDA-approved.
Category
- Gastric/Esophageal Cancer
Format
- Live Webinar
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- CCM clock hours
- Participation
Recorded Presentation from the NCCN Pharmacy Updates: Updates in Biomarker-Driven Therapy in Non-Small Cell Lung Cancer
The biomarker-driven treatment of non-small cell lung cancer is evolving rapidly and pharmacists should be aware of new data, therapies, and treatment recommendations in order to support the multidisciplinary health care team and provide optimal patient care.
Category
- Lung Cancers
Format
- Recorded Webcast
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- Participation
NCCN Guidelines® Insights - Prostate Cancer, Version 1.2023
These NCCN Guidelines Insights summarizes much of the panel’s discussions for the 4.2022 and 1.2023 updates to the guidelines regarding systemic therapy for metastatic prostate cancer.
Category
- Prostate Cancer
Format
- Monograph/Journal Supplement
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- Participation
The Importance of Re-Vaccination After Cellular Therapy
Cellular therapies are associated with an increased infection risk, and vaccination in these survivors plays a critical role in lowering that risk. Clinicians need to be educated on the importance of vaccination in these survivors as well as the details of dosing and timing of vaccines to best protect this vulnerable population from vaccine-preventable diseases.
Category
- Hematologic Malignancies
Format
- Recorded Webcast
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- Participation